[Updated studies on the immunotherapy of prostate cancer]

Prostate cancer (PCa) is a common urogenital malignancy in elderly men, for which current treatment strategies include surgery, radiotherapy, chemotherapy and androgen-deprivation therapy. However, PCa patients with recurrence or metastasis may ultimately develop therapeutic resistance. Recent studies show that PCa is an immunosensitive tumor and immunotherapy is a feasible option for its treatment, which involves therapeutic vaccination, immune checkpoint inhibitors, tumor microenvironment regulators, bi-specific antibodies, and adoptive cell metastasis. The application of immunotherapy, however, has been hindered by the adverse reactions of the patients and limited effects of single-drug medication. Individualized treatment and combination therapy are expected to be the alternatives in the development of the treatments of PCa.